Condition
Metastatic Cervical Cancer clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Metastatic Cervical Cancer clinical trials that are recruiting, at sites in 4 countries (most in United States (2), Belarus (1), China (1)). By phase: Phase 2 (2), Phase 2/3 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 4Countries
Newest Metastatic Cervical Cancer clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| PD-1 versus PD-L1 immunotherapy combined with chemotherapy, with or without bevacizumab, for advanced cervical cancer. | Phase 2/3 | Minsk, Lesnoy | Recruiting | Mar 16, 2026 |
| SHR-A2102 versus investigator's choice chemotherapy for recurrent or metastatic cervical cancer after platinum and PD-(L)1 therapy | Phase 3 | Guangzhou, Guangdong | Recruiting | Feb 18, 2026 |
| Understanding cervical cancer treatment and characteristics in Italy | — | Bologna, Bologna and 10 other locations | Recruiting | Jan 13, 2025 |
| Combination treatment for recurrent or metastatic cervical cancer | Phase 2 | Little Rock, Arkansas and 2 other locations | Recruiting | Dec 5, 2023 |
| Combination therapy of pembrolizumab and lenvatinib for advanced cervical cancer | Phase 2 | Washington D.C., District of Columbia and 3 other locations | Recruiting | Apr 29, 2021 |
All recruiting trials (5)
-
PD-1 versus PD-L1 immunotherapy combined with chemotherapy, with or without bevacizumab, for advanced cervical cancer.
This trial tests whether giving PD-1 or PD-L1 immunotherapy alongside chemotherapy, with or without bevacizumab, helps adults with metastatic, persistent, or recurrent cervical cancer.
-
SHR-A2102 versus investigator's choice chemotherapy for recurrent or metastatic cervical cancer after platinum and PD-(L)1 therapy
This trial tests whether SHR-A2102 works better than standard chemotherapy for people with recurrent or metastatic cervical cancer whose disease progressed after platinum-based chemotherapy and PD-(L)1 inhibitors.
-
Understanding cervical cancer treatment and characteristics in Italy
This study looks at how patients in Italy with advanced or recurring cervical cancer are treated and what their experiences are like.
-
Combination treatment for recurrent or metastatic cervical cancer
This study is testing if adding a new treatment called PRGN-2009 to pembrolizumab can help people with recurrent or metastatic cervical cancer who haven't responded to pembrolizumab alone.
-
Combination therapy of pembrolizumab and lenvatinib for advanced cervical cancer
This study is testing if a combination of two drugs, pembrolizumab and lenvatinib, can help patients with advanced cervical cancer who haven't had success with other treatments.
Related topics
Quick answers
How many Metastatic Cervical Cancer clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in United States (2 trials), Belarus (1 trial), China (1 trial), Italy (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 2/3: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.